Literature DB >> 29175968

Learning health systems, clinical equipoise and the ethics of response adaptive randomisation.

Alex John London.   

Abstract

To give substance to the rhetoric of 'learning health systems', a variety of novel trial designs are being explored to more seamlessly integrate research with medical practice, reduce study duration and reduce the number of participants allocated to ineffective interventions. Many of these designs rely on response adaptive randomisation (RAR). However, critics charge that RAR is unethical on the grounds that it violates the principle of equipoise. In this paper, I reconstruct critiques of RAR as holding that it is inconsistent with five important ethical principles. I then argue that these criticisms rest on a faulty view of equipoise encouraged by the idea that a RAR study models the beliefs of a single rational agent about the relative merits of the interventions being studied. I outline a view in which RAR models an idealised health system in which diverse communities of fully informed experts shrink or grow as their constituent members update their expert opinions in light of reliable medical evidence. I show how a proper understanding of clinical equipoise can reconcile this conception of RAR with these five ethical principles. This analysis removes an in-principle objection to RAR and sheds important light on the relationship between clinical equipoise and transient diversity in the scientific community. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  biostatistics; clinical trials; ethics; research ethics

Mesh:

Year:  2017        PMID: 29175968     DOI: 10.1136/medethics-2017-104549

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  10 in total

1.  Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial.

Authors:  Benjamin T King; Patrick D Lawrence; Truman J Milling; Steven J Warach
Journal:  Int J Stroke       Date:  2019-08-18       Impact factor: 5.266

2.  Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.

Authors:  Nir Eyal; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-22       Impact factor: 11.205

Review 3.  Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial.

Authors:  Seema K Shah; Alex John London; Lynne Mofenson; James V Lavery; Grace John-Stewart; Patricia Flynn; Gerhard Theron; Shrikhant I Bangdiwala; Dhayendre Moodley; Lameck Chinula; Lee Fairlie; Tumalano Sekoto; Tebogo J Kakhu; Avy Violari; Sufia Dadabhai; Katie McCarthy; Mary Glenn Fowler
Journal:  Clin Trials       Date:  2021-09-15       Impact factor: 2.599

4.  The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.

Authors:  Alessio Crippa; Bram De Laere; Andrea Discacciati; Berit Larsson; Jason T Connor; Erin E Gabriel; Camilla Thellenberg; Elin Jänes; Gunilla Enblad; Anders Ullen; Marie Hjälm-Eriksson; Jan Oldenburg; Piet Ost; Johan Lindberg; Martin Eklund; Henrik Grönberg
Journal:  Trials       Date:  2020-06-26       Impact factor: 2.279

5.  Embedded point of care randomisation for evaluating comparative effectiveness questions: PROSPECTOR-critical care feasibility study protocol.

Authors:  Matthew G Wilson; Folkert W Asselbergs; Ruben Miguel; David Brealey; Steve K Harris
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

Review 6.  Clinical deployment environments: Five pillars of translational machine learning for health.

Authors:  Steve Harris; Tim Bonnici; Thomas Keen; Watjana Lilaonitkul; Mark J White; Nel Swanepoel
Journal:  Front Digit Health       Date:  2022-08-19

7.  Ethics of randomized trials in a public health emergency.

Authors:  Alex John London; Olayemi O Omotade; Michelle M Mello; Gerald T Keusch
Journal:  PLoS Negl Trop Dis       Date:  2018-05-17

Review 8.  Heterogeneous perception of the ethical legitimacy of unbalanced randomization by institutional review board members: a clinical vignette-based survey.

Authors:  Clarisse Dibao-Dina; Agnès Caille; Bruno Giraudeau
Journal:  Trials       Date:  2018-08-14       Impact factor: 2.279

9.  Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.

Authors:  Thomas Burnett; Pavel Mozgunov; Philip Pallmann; Sofia S Villar; Graham M Wheeler; Thomas Jaki
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775

10.  Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.

Authors:  Kim May Lee; Louise C Brown; Thomas Jaki; Nigel Stallard; James Wason
Journal:  Trials       Date:  2021-03-10       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.